CO2019005207A2 - Complejo medicinal para tratar diabetes tipo 2 y dislipidemia diabética - Google Patents

Complejo medicinal para tratar diabetes tipo 2 y dislipidemia diabética

Info

Publication number
CO2019005207A2
CO2019005207A2 CONC2019/0005207A CO2019005207A CO2019005207A2 CO 2019005207 A2 CO2019005207 A2 CO 2019005207A2 CO 2019005207 A CO2019005207 A CO 2019005207A CO 2019005207 A2 CO2019005207 A2 CO 2019005207A2
Authority
CO
Colombia
Prior art keywords
diabetes
medicinal complex
treat type
diabetic dyslipidemia
medicinal
Prior art date
Application number
CONC2019/0005207A
Other languages
English (en)
Inventor
Ki Sook Park
Hye Jin Yoon
Jong Hyuk Jung
Sung Won Kim
Ji Yoon Kim
Seok Cheol Yoo
Ri Sun Kim
Jae Soon Ahn
Original Assignee
Lg Chemical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62146049&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO2019005207(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lg Chemical Ltd filed Critical Lg Chemical Ltd
Publication of CO2019005207A2 publication Critical patent/CO2019005207A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

RESUMEN DE LA INVENCIÓN La presente invención se relaciona a un complejo medicinal para tratar efectivamente diabetes tipo 2 y dislipidemia de pacientes diabéticos, más específicamente, la presente invención proporciona un complejo medicinal que comprende un inhibidor de peptidasa IV, gemigliptin o una sal farmacéuticamente aceptable del mismo, y un inhibidor de HMG-CoA reductasa, rosuvastatina o una sal farmacéuticamente aceptable del mismo, para controlar efectivamente los niveles de azúcar en la sangre y mejorar factores de riesgo de la enfermedad cardiovascular.
CONC2019/0005207A 2016-11-15 2019-05-22 Complejo medicinal para tratar diabetes tipo 2 y dislipidemia diabética CO2019005207A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20160152195 2016-11-15
PCT/KR2017/012941 WO2018093144A1 (ko) 2016-11-15 2017-11-15 제2형 당뇨병 및 당뇨성 이상지질혈증 치료용 복합제제

Publications (1)

Publication Number Publication Date
CO2019005207A2 true CO2019005207A2 (es) 2019-08-20

Family

ID=62146049

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2019/0005207A CO2019005207A2 (es) 2016-11-15 2019-05-22 Complejo medicinal para tratar diabetes tipo 2 y dislipidemia diabética

Country Status (9)

Country Link
KR (1) KR102055894B1 (es)
CN (1) CN109996545A (es)
BR (1) BR112019009709A2 (es)
CO (1) CO2019005207A2 (es)
MX (1) MX2019005572A (es)
PE (1) PE20191502A1 (es)
PH (1) PH12019501028A1 (es)
RU (1) RU2721406C1 (es)
WO (1) WO2018093144A1 (es)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0322552D0 (en) * 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
AU2006239929B2 (en) * 2005-04-22 2011-11-03 Alantos Pharmaceuticals Holding, Inc. Dipeptidyl peptidase-IV inhibitors
WO2011018185A2 (en) * 2009-08-13 2011-02-17 Synthon B.V. Pharmaceutical tablet comprising rosuvastatin calcium
AU2010323068B2 (en) * 2009-11-27 2015-09-03 Boehringer Ingelheim International Gmbh Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin
WO2011139256A2 (en) * 2010-05-04 2011-11-10 Bilgic Mahmut Stable rosuvastatin formulations
KR20140013436A (ko) * 2012-07-24 2014-02-05 한미약품 주식회사 메트포르민 및 로수바스타틴을 포함하는 경구용 복합 제제
UY35065A (es) * 2012-10-08 2014-05-30 Lg Life Sciences Ltd Fármaco combinado que comprende gemigliptina y metformina y método para su preparación
WO2014080383A1 (en) * 2012-11-26 2014-05-30 Ranbaxy Laboratories Limited Pharmaceutical composition of dipeptidyl peptidase-iv (dpp-iv) inhibitors in combination with other antidiabetics
TW201513857A (zh) * 2013-07-05 2015-04-16 Cadila Healthcare Ltd 協同性組成物
CN103494788B (zh) * 2013-10-10 2015-08-05 齐晓彤 瑞舒伐他汀钙片的药物组合物及其制备方法
CN104473929B (zh) * 2014-12-17 2018-05-29 深圳翰宇药业股份有限公司 一种西格列汀辛伐他汀缓释组合物

Also Published As

Publication number Publication date
KR102055894B1 (ko) 2019-12-13
KR20180054500A (ko) 2018-05-24
MX2019005572A (es) 2019-08-14
CN109996545A (zh) 2019-07-09
BR112019009709A2 (pt) 2019-08-13
WO2018093144A1 (ko) 2018-05-24
PE20191502A1 (es) 2019-10-22
RU2721406C1 (ru) 2020-05-19
PH12019501028A1 (en) 2020-01-20

Similar Documents

Publication Publication Date Title
CL2023002682A1 (es) Uso de inhibidores de ehmt2 para tratar trastornos sanguíneos
EA202090955A1 (ru) Способы применения ингибиторов ehmt2 в лечении или предупреждении нарушений со стороны крови
EA201691320A1 (ru) Способы лечения пациентов с гиперхолестеринемией, которая устойчива к терапии умеренными дозами статинов
CO2017011197A2 (es) Terapia de combinación fgfr/pd-1 para el tratamiento del cancer
CO2017004715A2 (es) Métodos y formulaciones para tratar enfermedades vasculares de los ojos
MX2022013172A (es) Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia.
MX2021000898A (es) Inhibidores de pcsk9 para usarse en el tratamiento de pacientes con hipercolesterolemia familiar heterocigota (hfhe).
BR112015009948A8 (pt) Antagonistas de ativina-actrii, usos dos mesmos para tratamento de doenças ósseas e outros distúrbios e método para monitorar a eficácia do tratamento ou prevenção de uma doença óssea e outros distúrbios
WO2015117010A3 (en) Bag3 as a target for therapy of heart failure
CL2015002608A1 (es) Compuesto de amino-pirazol y usos medicinales relacionados.
CL2019001214A1 (es) Composición farmacéutica, métodos para tratamiento y sus usos.
BR112018007026A2 (pt) composto, método de modulação da atividade de gaba-at, método para a modulação dos níveis de dopamina, método para o tratamento da dependência de substâncias, método de modulação da atividade de ornitina aminotransferase, método de redução da atividade de uma ornitina aminotransferase expressa por um carcinoma hepatocelular humano e método para o tratamento de distúrbios psicológicos e neurológicos
MX2021000289A (es) Inhibidores pcsk9 para usarse en el tratamiento de hipercolesterolemia.
MX2016011975A (es) Metodos para reducir el riesgo cardiovascular.
BR112015026021A2 (pt) terapia de combinação compreendendo um inibidor de tor quinase e n-(3-(5-flúor-2-(4-(2-met-oxietoxi)fenilamino)pirimidin-4-ilamino)fenil)acrilamida para o tratamento de câncer
EA201890891A1 (ru) Биомаркеры, связанные с заболеваниями, опосредованными интерлейкином-33 (ил-33), и их применение
AR092899A1 (es) Uso de masitinib para el tratamiento del cancer en subpoblaciones de pacientes identificados que utilizan factores de prediccion
CL2017001756A1 (es) Régimen de dosificación para antagonistas de madcam.
CL2021001623A1 (es) Terapia de combinación con un inhibidor de raf y un inhibidor de cdk4/6 para utilizar en el tratamiento del cáncer
CO2017001899A2 (es) Tratamiento del cáncer con el inhibidor de la alfa-amilasa en los animales de compañía
CO2019005207A2 (es) Complejo medicinal para tratar diabetes tipo 2 y dislipidemia diabética
EA202091653A1 (ru) Миноциклин для лечения воспалительных заболеваний кожи
BR112014032264A8 (pt) Composiçâo para tratamento ou prevençâo de doenças relacionadas á permeabilidade vascular, contendo imatinibe ou um sal farmaceuticamente aceitável respectivo como ingrediente ativo
CY1123322T1 (el) Φαρμακευτικη συνθεση περιλαμβανουσα μπισοπρολολη και περινδροπριλη
DOP2014000258A (es) Tratamiento de la metástasis en el cerebro con una combinación de veliparib y una terapia con radiación en la totalidad del cerebro